Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Opposing roles of STAT1 and STAT3 in T cell–mediated hepatitis: regulation by SOCS
Feng Hong, … , Van-Anh Nguyen, Bin Gao
Feng Hong, … , Van-Anh Nguyen, Bin Gao
Published November 15, 2002
Citation Information: J Clin Invest. 2002;110(10):1503-1513. https://doi.org/10.1172/JCI15841.
View: Text | PDF
Article Hepatology Article has an altmetric score of 3

Opposing roles of STAT1 and STAT3 in T cell–mediated hepatitis: regulation by SOCS

  • Text
  • PDF
Abstract

Research Article

Authors

Feng Hong, Barbara Jaruga, Won Ho Kim, Svetlana Radaeva, Osama N. El-Assal, Zhigang Tian, Van-Anh Nguyen, Bin Gao

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
STAT3 and SOCS3 activation are attenuated, but liver injury, STAT1, IRF-...
STAT3 and SOCS3 activation are attenuated, but liver injury, STAT1, IRF-1, and SOCS1 activation are enhanced in Con A–induced hepatitis in IL-6–/– mice. (a) IL-6+/+ mice and IL-6–/– mice were injected with 10 μg/g of Con A. At various time points, liver protein extracts and RNA were analyzed by Western blot or RT-PCR (indicated by asterisks), respectively, using Ab’s and primers as indicated (left panel), and quantified by PhosphorImager analysis (right panel). The values are shown as means ± SEM from four independent experiments. *P < 0.001, #P < 0.01, §P < 0.05 vs. corresponding control groups at the same time point. (b) Serum ALT levels from these mice were measured. Values are shown as means ± SEM from four mice at each time point. (c) Photomicrographs of representative mouse livers obtained 9 hours after Con A injection with H&E staining are shown (original magnification ×200 and ×400). White arrows indicate massive necrosis observed in the liver. (d) Wild-type control and IL-6–/– mice were injected with Con A (10 μg/g). At various time points, serum IFN-γ levels were measured. Values are shown as means ± SEM from three mice at each time point. *P < 0.001 vs. corresponding Con A-treated wild-type control groups at the same time points. (e) C57BL/6J mice were injected (intravenously) with IL-6 (2 μg/g), followed 6 hours later by injection of Con A (10 μg/g). After 8 hours, serum ALT levels were measured. Values shown are means ± SEM from five mice. Significant difference from corresponding Con A–treated group is indicated by asterisks. *P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
23 readers on Mendeley
See more details